en.unionpedia.org

Intellia Therapeutics, the Glossary

Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies.^[1]

35 relations: AbbVie, Agios Pharmaceuticals, Atlas Venture, Beta thalassemia, Bioinformatics, Biological target, Biopharmaceutical, Biotechnology, Cambridge, Massachusetts, CAR T cell, Chief executive officer, Chief financial officer, CRISPR, CRISPR gene editing, Derrick Rossi, Drug delivery, Drug development, Familial amyloid polyneuropathy, Hematopoietic stem cell, Initial public offering, Jennifer Doudna, Luciano Marraffini, Novartis, President (corporate title), Public company, Rachel Haurwitz, Regeneron Pharmaceuticals, Rodolphe Barrangou, Russell 2000 Index, Sickle cell disease, Simon & Schuster, University of California, Berkeley, Vice president, Vilnius University, Virginijus Šikšnys.
Genomics companies
Pharmaceutical companies established in 2014

AbbVie

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. Intellia Therapeutics and AbbVie are biotechnology companies of the United States and pharmaceutical companies of the United States.

See Intellia Therapeutics and AbbVie

Agios Pharmaceuticals

Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. Intellia Therapeutics and Agios Pharmaceuticals are companies listed on the Nasdaq, Health care companies based in Massachusetts and pharmaceutical companies of the United States.

See Intellia Therapeutics and Agios Pharmaceuticals

Atlas Venture

Atlas Venture is an early-stage venture capital firm that creates and invests in biotechnology startup companies in the U.S. Atlas is headquartered in Cambridge, Massachusetts, where the majority of its investments are located.

See Intellia Therapeutics and Atlas Venture

Beta thalassemia

Beta thalassemias (β thalassemias) are a group of inherited blood disorders.

See Intellia Therapeutics and Beta thalassemia

Bioinformatics

Bioinformatics is an interdisciplinary field of science that develops methods and software tools for understanding biological data, especially when the data sets are large and complex.

See Intellia Therapeutics and Bioinformatics

Biological target

A biological target is anything within a living organism to which some other entity (like an endogenous ligand or a drug) is directed and/or binds, resulting in a change in its behavior or function.

See Intellia Therapeutics and Biological target

Biopharmaceutical

A biopharmaceutical, also known as a biological medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources.

See Intellia Therapeutics and Biopharmaceutical

Biotechnology

Biotechnology is a multidisciplinary field that involves the integration of natural sciences and engineering sciences in order to achieve the application of organisms and parts thereof for products and services.

See Intellia Therapeutics and Biotechnology

Cambridge, Massachusetts

Cambridge is a city in Middlesex County, Massachusetts, United States.

See Intellia Therapeutics and Cambridge, Massachusetts

CAR T cell

In biology, chimeric antigen receptors (CARs)—also known as chimeric immunoreceptors, chimeric T cell receptors or artificial T cell receptors—are receptor proteins that have been engineered to give T cells the new ability to target a specific antigen.

See Intellia Therapeutics and CAR T cell

Chief executive officer

A chief executive officer (CEO) (chief executive (CE), or managing director (MD) in the UK) is the highest officer charged with the management of an organization especially a company or nonprofit institution.

See Intellia Therapeutics and Chief executive officer

Chief financial officer

A chief financial officer (CFO), also known as a treasurer, is an officer of a company or organization who is assigned the primary responsibility for making decisions for the company for projects and its finances (financial planning, management of financial risks, record-keeping, and financial reporting, and often the analysis of data).

See Intellia Therapeutics and Chief financial officer

CRISPR

CRISPR (an acronym for clustered regularly interspaced short palindromic repeats) is a family of DNA sequences found in the genomes of prokaryotic organisms such as bacteria and archaea.

See Intellia Therapeutics and CRISPR

CRISPR gene editing

CRISPR gene editing (CRISPR, pronounced "crisper", refers to "clustered regularly interspaced short palindromic repeats") is a genetic engineering technique in molecular biology by which the genomes of living organisms may be modified.

See Intellia Therapeutics and CRISPR gene editing

Derrick Rossi

Derrick J. Rossi (born 5 February 1966), is a Canadian stem cell biologist and entrepreneur.

See Intellia Therapeutics and Derrick Rossi

Drug delivery

Drug delivery refers to approaches, formulations, manufacturing techniques, storage systems, and technologies involved in transporting a pharmaceutical compound to its target site to achieve a desired therapeutic effect.

See Intellia Therapeutics and Drug delivery

Drug development

Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery.

See Intellia Therapeutics and Drug development

Familial amyloid polyneuropathy

Familial amyloid polyneuropathy, also called transthyretin-related hereditary amyloidosis, transthyretin amyloidosis abbreviated also as ATTR (hereditary form), or Corino de Andrade's disease, is an autosomal dominant neurodegenerative disease.

See Intellia Therapeutics and Familial amyloid polyneuropathy

Hematopoietic stem cell

Hematopoietic stem cells (HSCs) are the stem cells that give rise to other blood cells.

See Intellia Therapeutics and Hematopoietic stem cell

Initial public offering

An initial public offering (IPO) or stock launch is a public offering in which shares of a company are sold to institutional investors and usually also to retail (individual) investors.

See Intellia Therapeutics and Initial public offering

Jennifer Doudna

Jennifer Anne Doudna (born February 19, 1964) is an American biochemist who has pioneered work in CRISPR gene editing, and made other fundamental contributions in biochemistry and genetics.

See Intellia Therapeutics and Jennifer Doudna

Luciano Marraffini

Luciano Marraffini (born July 17, 1974) is an Argentinian-American microbiologist.

See Intellia Therapeutics and Luciano Marraffini

Novartis

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland.

See Intellia Therapeutics and Novartis

President (corporate title)

A president is a leader of an organization, company, community, club, trade union, university or other group.

See Intellia Therapeutics and President (corporate title)

Public company

A public company is a company whose ownership is organized via shares of stock which are intended to be freely traded on a stock exchange or in over-the-counter markets.

See Intellia Therapeutics and Public company

Rachel Haurwitz

Rachel Elizabeth Haurwitz (born May 20, 1985) is an American biochemist and structural biologist.

See Intellia Therapeutics and Rachel Haurwitz

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Intellia Therapeutics and Regeneron Pharmaceuticals are biotechnology companies of the United States, companies listed on the Nasdaq and pharmaceutical companies of the United States.

See Intellia Therapeutics and Regeneron Pharmaceuticals

Rodolphe Barrangou

Rodolphe Barrangou is the Todd R. Klaenhammer Distinguished Professor in Probiotics Research in the Department of Food, Bioprocessing and Nutrition Sciences at North Carolina State University; Co-Founder and Chief Executive Officer of CRISPR Biotechnologies; Co-Founder and Chief Scientific Officer of Ancilia Biosciences; Co-Founder, President and Chief Scientific Officer of TreeCo; and Co-Founder and member of the Scientific Advisory Board of Intellia Therapeutics.

See Intellia Therapeutics and Rodolphe Barrangou

Russell 2000 Index

The Russell 2000 Index is a small-cap U.S. stock market index that makes up the smallest 2,000 stocks in the Russell Index.

See Intellia Therapeutics and Russell 2000 Index

Sickle cell disease

Sickle cell disease (SCD), also simply called sickle cell, is a group of hemoglobin-related blood disorders typically inherited.

See Intellia Therapeutics and Sickle cell disease

Simon & Schuster

Simon & Schuster LLC is an American publishing company owned by Kohlberg Kravis Roberts.

See Intellia Therapeutics and Simon & Schuster

University of California, Berkeley

The University of California, Berkeley (UC Berkeley, Berkeley, Cal, or California) is a public land-grant research university in Berkeley, California.

See Intellia Therapeutics and University of California, Berkeley

Vice president

A vice president or vice-president, also director in British English, is an officer in government or business who is below the president (chief executive officer) in rank.

See Intellia Therapeutics and Vice president

Vilnius University

Vilnius University (Lithuanian: Vilniaus universitetas) is a public research university, which is the first and largest university in Lithuania, as well as one of the oldest and most prominent higher education institutions in Central and Eastern Europe.

See Intellia Therapeutics and Vilnius University

Virginijus Šikšnys

Virginijus Šikšnys (born 26 January 1956) is a Lithuanian biochemist and a professor at Vilnius University.

See Intellia Therapeutics and Virginijus Šikšnys

References

[1] https://en.wikipedia.org/wiki/Intellia_Therapeutics

Intellia Therapeutics, the Glossary

Table of Contents

See also

Genomics companies

Pharmaceutical companies established in 2014

References